NEC Baby Formula Lawsuit
The NEC Baby Formula Lawsuit now stands among the most serious product liability disputes involving infant nutrition in the United States. Parents of premature babies bring claims that cow milk-based formulas such as Similac and Enfamil contributed to necrotizing enterocolitis, or NEC, in medically fragile infants. Plaintiffs argue that manufacturers understood the elevated risk and failed to warn doctors and caregivers who relied on those formulas inside neonatal intensive care units. Pressure around those claims has grown fast.
Medical evidence gives the dispute sharp weight. NEC attacks the intestine. Doctors report rapid tissue death. Surgeons describe bowel perforations and dangerous infection spreading into the bloodstream. Mortality rates in premature infants can reach between fifteen percent and forty percent. Those numbers appear in clinical evidence presented to juries in major cases. Parents describe emergency operations, ostomy care, long recovery periods, and permanent developmental injuries. Lawyers now present the litigation as a conflict between long-standing formula practices and newer findings that highlight the protective effect of human milk for preterm infants.
Federal court filings show that the NEC Baby Formula Lawsuit has moved well past early investigative stages. A consolidated multidistrict litigation groups hundreds of claims against Abbott Laboratories and Mead Johnson in the Northern District of Illinois under MDL No. 3026. Recent reports identify about seven hundred seventy to seven hundred seventy-four active cases in that MDL as of late 2025. State-court filings continue to rise in multiple jurisdictions. Jury trials already produced large numbers, including a sixty million dollar verdict against Mead Johnson in March 2024 and a four hundred ninety-five million dollar verdict against Abbott in July 2024. Investors now track the litigation closely. Regulators also monitor emerging evidence as parents and hospitals wait for the next phase of the legal process.
How The NEC Baby Formula Lawsuits Started
Early signals came from neonatal units, medical journals, and cautious neonatologists. Research over many years showed higher NEC rates in very premature and very low birth-weight infants who received cow milk-based formula or fortifiers instead of human milk. Lawyers then began to connect that body of research to real families. Law firm records show at least one major NEC formula case filed in May 2021 against a Similac maker on behalf of parents whose preterm baby died in 2019.
Class-action and mass-tort-oriented practices soon opened dedicated NEC baby formula pages. Those pages encouraged parents of premature infants who developed NEC after exposure to specific Similac or Enfamil products, including human milk fortifiers, to seek legal review. Product lists on those sites pointed to Similac Special Care, Similac Neosure, Enfamil Human Milk Fortifier, and similar preterm formulas. Claims alleged failure to warn and misrepresentation of safety when contrasted with donor milk or maternal breast milk.
Pressure then shifted to federal courts. In April 2022, the Judicial Panel on Multidistrict Litigation centralized federal NEC infant formula lawsuits into MDL No. 3026 in Chicago before Chief Judge Rebecca R. Pallmeyer. The MDL structure allowed coordinated discovery, common expert disputes, and bellwether trials. At the same time, plaintiffs’ lawyers also pursued state-court actions, including clusters in Illinois and Missouri, where juries could hear individual stories faster than a federal bellwether schedule sometimes allows.
Background Of The NEC Baby Formula Litigation
Medical debate sits at the center of the NEC litigation. Many pediatric and neonatal researchers agree that the absence of human milk increases NEC risk in very premature infants. Human milk carries protective factors that formula cannot fully match. Lawsuits argue that manufacturers continued to promote cow milk-based products for preterm infants despite decades of data about differential risk.
Product lines under scrutiny include specialized preterm formulas and fortifiers. Public complaint summaries and law firm resources repeatedly mention Similac Special Care, Similac Neosure, Similac Human Milk Fortifier, Enfamil Human Milk Fortifier, and other cow milk-based formulations for fragile preemies. Many of those products entered NICUs under standard feeding protocols that blended human milk with fortifiers or shifted to formula when maternal supply lagged. Hospitals depended on sales representatives and clinical marketing materials that positioned formulas as appropriate or even preferred for growth.
Professional groups have also weighed in. An American Academy of Pediatrics communication in 2022 called for greater use of maternal or donor human milk for preterm infants and expressed concern about aggressive formula marketing in maternity settings. A 2025 paper in Pediatric Research reviewed the NEC litigation and noted that some verdicts held formula makers liable while evidence still left open questions about causation and the precise role of cow milk-based products.
Regulators have taken a narrower line so far. An FDA information page on infant formula emphasizes contamination risks and manufacturing controls but does not issue a specific NEC warning for cow milk-based products. A working group convened by U.S. agencies and NIH scientists recently concluded that current evidence does not prove that the formula causes NEC, while also acknowledging the strong protective effect of human milk. Those statements now appear in court briefings as manufacturers push back against causal language in expert reports.
Key Allegations Against Formula Manufacturers
Plaintiffs anchor their cases in failure-to-warn theories. Complaints say that Abbott and Mead Johnson knew, or should have known, that cow milk-based formulas greatly increased NEC risk in premature infants when compared with exclusive human milk feeding. Lawyers argue that companies had access to decades of studies documenting higher NEC rates in formula-fed preterm infants with very low birth weight. Allegations also accuse manufacturers of marketing formulas as safe, necessary, or superior for growth in premature babies without clear risk disclosures for NEC.
Design-defect and negligence theories also appear. Some complaints claim that formulas used cow milk and additives in ways that placed the most fragile infants at unacceptable risk when safer options such as donor milk or human milk-based fortifiers existed. Marketing materials and sample programs in hospitals face scrutiny for encouraging reliance on formula in NICUs that already struggle with breastfeeding support.
Manufacturers flatly deny wrongdoing. Abbott and Mead Johnson tell courts and investors that products remain safe when used under medical supervision and form part of the standard of care for premature infants. Company statements point to official reports that stop short of saying formula causes NEC and highlight the crucial role that human milk, not the alleged “toxicity” of formula, plays in risk reduction. Trade groups and some medical organizations also warn that litigation outcomes could chill use of a tool that many NICUs still see as necessary in some situations.
Timeline Of The NEC Baby Formula Case
Early Complaints And Consumer Signals
Families of preterm infants began to connect NEC diagnoses to formula feeding patterns long before MDL consolidation. Keller Postman reports filing a major NEC infant formula complaint in May 2021 on behalf of parents whose premature baby died after Similac feedings, marking one of the earliest widely cited suits. Other firms soon followed with similar claims, and at least fifty Similac and Enfamil lawsuits had been filed by 2021, according to one plaintiff-side source tracking Illinois filings and consolidation motions. ClassAction.org and related sites then added NEC infant formula investigations to public lists of open cases, telling parents that lawsuits alleged heightened NEC risks from cow milk-based Similac and Enfamil products in premature infants.
Hospital-level concerns grew in parallel. Medical literature and NICU quality projects tracked NEC clusters and compared outcomes for infants fed maternal milk, donor milk, and formula, with studies often showing higher NEC rates in formula-fed preterm infants. Human milk banks and advocacy organizations began to publish plain-language overviews of litigation that described claims against Enfamil and Similac, while reiterating that correlation did not automatically prove causation.
Company Response
Corporate responses came through press statements, investor calls, and courtroom filings. Reckitt, which owns Mead Johnson, and Abbott both deny that Enfamil or Similac causes NEC. Company representatives stress that NEC has many risk factors, including prematurity itself, low birth weight, infection, and intestinal immaturity. Statements from the companies describe formulas as scientifically tested products used under physician guidance in high-acuity settings.
Share-price reactions show how seriously markets take the litigation. A 60 million dollar verdict against Mead Johnson in March 2024 erased nearly 7 billion dollars in market value for Reckitt in a single trading session, according to major financial outlets. A 495 million dollar verdict against Abbott in July 2024 then sent that company’s shares lower and increased investor concern that combined NEC exposure could reach into the billions. Analysts emphasize that ultimate settlement costs remain uncertain and could end up lower than top-line scenarios, but investor anxiety has not disappeared.
Court Filings And Legal Steps
Formal consolidation shaped the federal landscape in 2022. An April 2022 JPML order created MDL No. 3026, In re Abbott Laboratories et al., Preterm Infant Nutrition Products Liability Litigation, in the Northern District of Illinois, and assigned Chief Judge Rebecca R. Pallmeyer. An October 2025 JPML summary listed 761 NEC infant formula cases pending in that MDL, with 898 total filed there since creation. Oberheiden Law Group, which tracks the docket, later reported 755 pending cases as of November 3, 2025, and 919 total filed, reflecting dismissals and other case movements. Other plaintiffs’ firms and mass-tort resources now estimate around 770 to 774 active NEC baby formula cases in the MDL heading into December 2025.
Bellwether scheduling has become a key driver. Court orders describe a first wave of bellwether trials followed by setbacks for plaintiffs, including summary judgment wins for Abbott in early MDL cases when judges excluded certain causation experts. Subsequent orders now direct both sides to prepare a second wave of bellwether trials for August 2026, with detailed protocols for case selection and discovery. State-court NEC cases run on their own schedules, with some trials already completed and more settings expected in 2025 and 2026.
Judge Notes Or Judicial Signals
Judicial rulings in 2024 and 2025 send mixed messages. In March 2024, the Illinois state court that heard the Watson Enfamil case allowed plaintiffs’ experts to testify that cow milk-based formula contributed to NEC and death in a premature infant. Jurors then delivered the 60 million dollar verdict. In July 2024, a Missouri jury in another case against Abbott issued a $495 million verdict that tied Similac to NEC in a preterm baby and placed a large amount on the alleged failure to warn.
Federal rulings show a more complex picture. A May 2025 Reuters report noted that Judge Pallmeyer allowed expert testimony in the MDL that Abbott and Mead Johnson preterm formulas can cause NEC, keeping hundreds of cases alive. That same report explained that the judge also entered judgment for Abbott in another case involving an infant death after NEC, finding the plaintiffs had not met proof standards on warnings and alternatives. MDL orders highlighted by Oberheiden Law Group reveal further Daubert battles, including the exclusion of at least one defense expert after he admitted using inaccurate figures. At least one Missouri state court has now ordered a new NEC trial after a prior defense verdict, citing improper conduct by defense counsel.
Government Or Regulatory Actions
Regulators have not issued the type of warning that plaintiffs sometimes reference in other mass torts. Federal-lawyer’s regulatory review notes that no official FDA warning specifically links NEC to cow milk-based infant formula. FDA communications instead focus on contamination risks such as Cronobacter and Salmonella and on manufacturing controls, including a March 2023 letter pushing formula makers to tighten safety programs and report positive contamination findings even when products have not yet reached consumers.
A broader scientific and regulatory working group convened by NIH and U.S. agencies issued a joint report stating that current evidence does not support the conclusion that formula causes NEC. The report still acknowledged that human milk lowers risk and that feeding choices in NICUs need careful balancing of benefits and harms. The American Academy of Pediatrics filed a brief supporting Mead Johnson’s appeal of the 60 million dollar verdict, arguing that over-simplified causation claims could interfere with medically guided use of formula in some premature infants.
Settlement Timeline
Global settlement remains out of reach at the end of 2025. No comprehensive NEC baby formula settlement program has been announced in either the MDL or key state-court venues. Existing numbers come from individual verdicts and a running tally of total trial awards. Drugwatch estimates that litigated NEC infant formula cases have produced about 555 million dollars in combined jury awards across Abbott and Mead Johnson trials so far. Lawyers quoted on that site suggest that eventual settlement payouts, if a program emerges, could land in broad ranges from roughly 50,000 dollars for less severe injury claims up to around 600,000 dollars or more for catastrophic harm or death. That range appears as an estimate, not a binding schedule.
Industry analysts and some plaintiff firms expect that outcomes of the next bellwether wave in 2026 will push parties closer to serious settlement talks. For now, each verdict or defense win shifts perceived leverage but does not settle the overall question of liability for hundreds of families still in line.
Current Status
December 2025 finds the NEC baby formula litigation in a mature but unsettled phase. JPML data and law firm tallies indicate roughly 770 to 774 active NEC infant formula cases pending in MDL No. 3026, along with dozens or hundreds more in state courts. Judge Pallmeyer has directed parties to prepare a second wave of bellwether trials for August 2026 after earlier MDL test cases ended in summary judgment or other pretrial resolutions. State-court NEC trials will likely continue in 2025 and 2026, including retrials in some venues where judges granted new trials after prior defense verdicts.
Public coverage now reflects an uneasy equilibrium. Some doctors warn that litigation may deter use of formula needed in complex cases, while plaintiffs’ experts emphasize that nothing in the science erases the clear protective effect of human milk or the higher NEC rates seen in formula-fed preterm infants. Parents who already filed still wait for either trial settings or settlement talks. Parents now hearing about the litigation for the first time can still find law firms accepting NEC baby formula cases for premature infants who developed the disease within the applicable limitation periods.
Additional Case Details
Eligibility discussions in NEC baby formula lawsuits tend to focus on several recurring factors. Law firm intake criteria often ask whether the child was born premature, received cow milk-based Similac or Enfamil products in a NICU or hospital setting, developed NEC confirmed by medical records, and required surgery or intensive treatment. Wrongful death claims arise when the infant died after NEC and treating records document formula use during the relevant window. Many firms also review birth weight, gestational age, and the presence of other risk factors identified in pediatric literature.
Case theories expand beyond manufacturers in some complaints. Several suits name hospitals or individual sales representatives as co-defendants. Allegations say that hospitals did not fully inform parents of NEC risks tied to cow milk-based products in preterm infants, or did not provide access to donor milk when possible. Some complaints also accuse sales representatives of overstating safety or minimizing risk when speaking with clinicians about feeding protocols.
Scientific nuance complicates every claim. A 2025 article in Pediatric Research and commentary from other researchers argue that NEC risk increases when human milk is absent rather than from a single toxic ingredient in formula. That line supports a view that broader feeding systems and lactation support matter as much as product design. Plaintiffs’ experts respond that the legal question centers on what manufacturers knew about differential risk for preterm babies and how clearly that information appeared on labels, marketing materials, and professional guidance.
Summary
NEC baby formula lawsuits now sit at the intersection of neonatal medicine, product liability, and public health policy. Families of premature infants argue that cow milk-based formulas such as Similac and Enfamil intensified NEC risk and that manufacturers failed to warn hospitals and parents about that danger. Manufacturers deny liability and point to official reports that stop short of naming the formula as a proven cause of NEC.
Courts have produced large verdicts on both sides of that divide and have also delivered defense wins and complex evidentiary rulings. Federal MDL No. 3026 and parallel state-court dockets will keep the issue alive into at least 2026 as new bellwether trials approach and settlement pressure slowly builds.
Sadia Parveen is a content writer at ClassAction24.com who creates informational articles on class action lawsuits, consumer protection matters, and legal developments. Her work focuses on researching publicly available information and presenting it in a clear and neutral format for general readers. She does not provide legal advice or professional legal services.
Musarat Bano serves as an editor at ClassAction24.com. She reviews articles for clarity, structure, and editorial consistency to ensure content remains factual, neutral, and suitable for informational publishing. Her role is limited to editorial review and presentation.
